3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
445
Carcinoma, Non-Small-Cell Lung
224
Breast Neoplasms
189
Ovarian Neoplasms
167
Glioblastoma
156
Neoplasms
126
Carcinoma, Hepatocellular
124
Rectal Neoplasms
112
Colonic Neoplasms
107
Neoplasm Metastasis
104
Brain Neoplasms
96
Lung Neoplasms
91
Fallopian Tube Neoplasms
85
Carcinoma, Renal Cell
71
Glioma
69
Pancreatic Neoplasms
54
Gliosarcoma
43
Melanoma
42
Liver Neoplasms
42
Uterine Cervical Neoplasms
40
Stomach Neoplasms
37
Adenocarcinoma of Lung
36
Recurrence
33
Astrocytoma
30
Endometrial Neoplasms
27
Carcinoma, Ovarian Epithelial
27
Triple Negative Breast Neoplasms
26
Prostatic Neoplasms
22
Kidney Neoplasms
22
Esophageal Neoplasms
21
Interventions
Sorafenib
5
lenvatinib
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sintilimab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
pembrolizumab
1
ozanimod
1
linifanib
1
genexol-PM
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
camrelizumab
1
belinostat
1
bavituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Liver Diseases
×
Bevacizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled